



Materialise
innovators you can count on



**Q3 2014 Financial Results
Conference Call
November 12, 2104**

Safe Harbor Summary

This presentation contains forward-looking statements regarding, among other things, the plans, objectives, expectations, strategies and prospects of the Company, both financial and business. Such statements are subject to known and unknown uncertainties and risks. When used in this presentation, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may”, “could”, “might”, “aim”, “should” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of the presentation. These expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, we cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of our forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from our expectations. We make no commitment, and disclaim any duty to update or revise any forward-looking statements to reflect future events or changes in our expectations. There are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this presentation.

We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.

This presentation presents non-IFRS financial measures, including Adjusted EBITDA. These measures are commonly used to compare operating results between periods or companies, but are not international financial reporting standards (IFRS).

Agenda



Fried Vancraen
Founder & CEO



Peter Leys
Executive Chairman



Frederic Merckx
CFO

- Q3 2014 Highlights
- Investing Our IPO Proceeds
- Q3 Financial Results and 2014 Guidance
- Q3 2014 Accomplishments, Q4 2014 Priorities
- Q&A

Q3 2014 Highlights

- Revenue increased 17% to 19,833 kEUR from prior year.
- 3D Printing software sales increased 29%
- Total software sales were 31% of total revenue
- Adjusted EBITDA, excluding non-cash based compensation expense, was 2,055 kEUR, or 10% of total revenue.
- R&D increased by 1,145 kEUR to 19% of total revenue.

Investing Our IPO Proceeds

Making Build versus Buy Decisions to Accelerate Growth

Build

- 3D Printing Software and Medical – investing in developing new products and expanding sales & marketing reach
- Industrial Production – developed eGrip for SHUNK
 - Demonstrates cross-fertilization of software, engineering and 3D printing production core competencies




Buy

- Acquired OrthoView for £8.47M*
- Adds new distribution channels for surgical pre-planning software tools and related 3D printed products
- Deal expected to be accretive to EPS within 12 months




* Excludes possible £0.36M earn out payment and £1.2M in cash and equivalents on OrthoView's balance sheet.

Consolidated Revenue




- ✓ 31% of Q3 2014 revenue from software sales.
- ✓ 39% of Q3 2014 revenue from end parts.


YTD 2014 Revenue




YTD 2013 Revenue




Consolidated Adjusted EBITDA



YTD 2014 Adj. EBITDA⁽¹⁾




YTD 2013 Adj. EBITDA⁽¹⁾



- ✓ Q3 2014 R&D spending increased 45% or 1,145 kEUR from prior year.
- ✓ Non-cash stock-based compensation expense in Q3 2014 was 282 kEUR.

(1) Excludes adjustments and eliminations.


3D Printing Software Segment



- ✓ Revenue from new licenses for Q3 2014 increased by 32% from the prior year.
- ✓ Q3 2014 revenue generated from OEMs increased by 53% from the prior year⁽¹⁾.
- ✓ YTD revenue from Asia increased by 35% from the prior year.
- ✓ Drop in Q3 EBITDA margin due to 828 kEUR increase in investment in R&D and S&M.

(1) Reflects a combination of 64% sales growth of software sold through OEMs to their customers and 34% sales growth of software sold to OEMs.

Medical Segment




- ✓ Q3 2014 medical software revenue decreased 2% from the prior year as a result of the accelerating conversion from perpetual to annual licenses.
- ✓ Share of annual licenses increased to 29% of new license sales from 7% last year.
- ✓ Q3 2014 revenue from direct sales of guides and implants increased by 53% from the prior year.
- ✓ Q3 2014 revenue from medical collaboration partners decreased 5% from the prior year.

Industrial Production Segment


Revenue

(€ in thousands)



EBITDA

Margin



- ✓ 37% growth in sales of end parts for Q3 2014 over the prior year.
- ✓ Number of printers increased from 115 as of 6/30/14 to 120 as of 9/30/14.
- ✓ Excluding growth businesses, Q3 2014 EBITDA margin increased to 19% from 16% for the prior year⁽¹⁾.

(1) Excluding growth businesses in Q3 2014, segment revenue was 6,960 kEUR and EBITDA was 1,311 kEUR versus revenue of 6,040 kEUR and EBITDA of 986 kEUR for Q3 2013.

Income Statement Highlights

(in thousands of euros, except where indicated)	Q3		YTD	
	2014	2013	2014	2013
Revenue	19,833	16,973	57,764	49,217
Cost of sales	<u>(7,679)</u>	<u>(6,282)</u>	<u>(22,853)</u>	<u>(18,697)</u>
Gross profit	12,154	10,691	34,911	30,520
Research & Development Expenses	(3,672)	(2,527)	(10,414)	(7,675)
Sales & Marketing Expenses	(6,382)	(5,417)	(18,218)	(15,676)
General & Administrative Expenses	(2,758)	(2,350)	(8,470)	(7,045)
Other income/(expenses), net	<u>1,401</u>	<u>1,281</u>	<u>3,422</u>	<u>2,834</u>
Operating profit	743	1,678	1,231	2,958
Financial income/(expenses), net	1,984	(181)	1,642	(496)
Share in loss of joint venture	(35)	(28)	(28)	-
Taxes	<u>(140)</u>	<u>(117)</u>	<u>(427)</u>	<u>(274)</u>
Net profit/(loss)	2,559	1,380	2,418	2,188
Diluted EPS* (euros)	0.05	0.04	0.06	0.06
Diluted weighted average shares (thousands)	49,142	38,057	42,602	38,034

* Excludes non-controlling interest.

Other Financial Highlights

(in thousands of euros)	09/30/2014	12/31/2013
Cash & equivalents	75,044	12,598
Receivables	14,087	12,382
Inventories	3,471	3,328
Payables	7,471	6,837
Total borrowings	17,243	16,316
Total equity	85,284	17,735
Total liabilities and equity	127,682	55,688
(in thousands of euros)	Q3 2014	Q3 2013
Capital expenditures	3,487	449
Cash flow from operations	28	3,090

2014 Guidance

**Consolidated
Revenue**

79M to 81M euros

**Consolidated
Adj. EBITDA⁽¹⁾**

5.0M to 6.0M euros

Note: These objectives do not represent budget estimates or projections of any type and have not been prepared by management in the manner budget estimates or projections are prepared. The Company's operational and financial objectives change from time to time based on numerous factors, and the Company's ability to achieve any objective is subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. For discussion of some of the important factors that could cause these variations, please consult the "Risk Factors" section of the prospectus filed with the SEC on June 26, 2014. Nothing in this presentation should be regarded as a representation by any person that these objectives will be achieved and the Company undertakes no duty to update its objectives.

(1) Adjusted EBITDA is a non-IFRS financial measure that the Company calculates as net profit plus income taxes, financial expenses (less financial income), depreciation and amortization and stock-based compensation expense.

2014 Operational Review

Q3 Operational Achievements

Software

- ✓ Entered new OEM agreements; strengthened existing OEM relationships
- ✓ Opened new office in China

Medical

- ✓ Renewed Zimmer partnership
- ✓ Successfully treated first patient with X-ray based knee guide technology
- ✓ Completed initial test phase of metal printers
- ✓ Acquired OrthoView

Industrial Production

- ✓ Collaborated with SCHUNK to develop eGrip design & ordering tool
- ✓ Advanced new contract opportunities to produce end parts

Q4 Operational Priorities

Software

- ✓ Further strengthen relationships with OEMs
- ✓ Form OEM partnerships to develop build processors

Medical

- ✓ Continue to advance X-ray product
- ✓ Complete testing of metal printers
- ✓ Begin integrating OrthoView

Industrial Production

- ✓ Focus on winning new, larger end parts contracts
- ✓ Better position RapidFit for consolidation of fixtures market

Q & A



Visionary company and leadership that has driven advancement of the 3D printing industry



Commitment to expanding 3D printing technology through constant ongoing Research & Development



At the forefront of 3D printing growth with a compelling and unique business and financial model

Adjusted EBITDA Reconciliation

	For the quarter ended September 30		For the nine months ended September 30	
(in thousands of euros)	2014	2013	2014	2013
Net profit/(loss)	2,559	1,380	2,418	2,188
Income taxes	140	117	427	274
Financial expense	412	221	821	608
Financial income	(2,395)	(40)	(2,462)	(112)
Depreciation & amortization	1,057	782	3,032	2,337
EBITDA	1,773	2,460	4,236	5,295
Non-recurring IPO Expenses	0	0	182	0
Non-cash stock-based compensation expenses	282	0	407	0
Adjusted EBITDA	2,055	2,460	4,825	5,295